IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

Study acronym: IMPROVE-AD
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 63 → 66 locations
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 6 of 14 entries
  2. Study sites: 62 to 63v12
  3. Study sites: 60 to 62
    • Eligibility criteria shortened, about 2 words
    v11
  4. Study sites: 57 to 60
    • Secondary endpoints: 16 to 14
    • Eligibility criteria expanded, about 5 words
    v10
  5. Study sites: 33 to 57v9
Show 7 earlier versionsHide 7 earlier versions
  1. Re-verified, no change to tracked fieldsv8
  2. Study sites: 15 to 33
    • Eligibility criteria expanded, about 2 words
    v7
  3. Primary completion date: Jun 2030 to Jun 1, 2030
    • Study completion date: Jun 2030 to Jun 30, 2030
    v6
  4. Study sites: 1 to 15
    • Start date changed from estimate of Jun 30, 2024 to Apr 14, 2024
    v5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Feb 2024 to Jun 30, 2024
    • Study sites: 0 to 1
    v4
  6. Start date: Dec 2023 to Feb 2024v3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Duke University
457 trials monitored
See 58 trials at risk
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Trial Details
NCT Number NCT06087029
Lead Sponsor Duke University
Collaborators: The University of Texas Health Science Center, Houston, State University of New York - Downstate Medical Center, Oregon Health and Science University, National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Type B Aortic Dissection
Enrollment 1,100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov